Investorideas.com

Call 800 665 0411 to learn about our services

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Target Price Boosted on Canadian Pharma Co.
December 1, 2022 (Investorideas.com Newswire) This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.

Biopharma Co. Now at a Bargain Price, Analyst Says
November 30, 2022 (Investorideas.com Newswire) Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report.

Expert Says Health Tech Co. Still in Good Spot To Buy
November 29, 2022 (Investorideas.com Newswire) Technical analyst Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you whether he believes it is a Buy.

Pharma Co. Won't See Bump in Sales From New COVID Drug
November 21, 2022 (Investorideas.com Newswire) The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatmen
November 15, 2022 (Investorideas.com Newswire) This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard.

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says
November 14, 2022 (Investorideas.com Newswire) With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors

2022-1114 - Name and Symbol Change - XPhyto Therapeutics Corp. (XPHY)
November 10, 2022 (Investorideas.com Newswire) XPhyto Therapeutics Corp. (XPHY) has announced a name and symbol change to BioNxt Solutions Inc. (BNXT).

Medical Device Co.'s Q2/22 Results Better Than Expect
November 10, 2022 (Investorideas.com Newswire) Along with improving its numbers during the quarter, this firm sold its first ultrasound ablation machines in North America

Clean Nuclear Med Tech With Quantum Blue Sky
November 10, 2022 (Investorideas.com Newswire) With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention.

Medical Device Stock News - Neovasc (NASDAQ: NVCN) Reducer Obtains U.S. Outpatient Reimbursement
Vancouver, British Columbia and Minneapolis, Minnesota - November 8, 2022 (Newsfile Corp.) (Investorideas.com Newswire) Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) today announced that the Centers for Medicare and Medicaid Services has assigned the Neovasc Reducer implant procedure a new outpatient reimbursement code payment status indicator

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

CORRECTION BY ISSUER: Universal PropTech Inc. Announces Agreement to Sell VCI Controls Inc
This document corrects and replaces in its entirety the press release issued earlier today. The following date, “December 2, 2022,” was added to the first paragraph and “arm's length” was added to the fourth paragraph. The updated release follows below:Toronto, Ontario--(Newsfile Corp. - December 5, 2022) - Universal PropTech Inc. (TSXV: UPI) ("UPI" or the "Company") announces that is has entered into a share purchase agreement dated December 2, 2022 (the "Agreement") with Dexterra Group...

Universal PropTech Inc. Announces Agreement to Sell VCI Controls Inc
Toronto, Ontario--(Newsfile Corp. - December 5, 2022) - Universal PropTech Inc. (TSXV: UPI) ("UPI" or the "Company") announces that is has entered into a share purchase agreement (the "Agreement") with Dexterra Group Inc. (TSX: DXT) (the "Purchaser") that provides for the sale (the "Transaction") of all of the issued and outstanding shares of the Company's wholly-owned subsidiary, VCI Controls Inc. ("VCI"). In consideration, the Purchaser will pay the Company an aggregate cash purchase price...

CVR Medical Corp. Announces Completion of 2022 3rd Quarter Financial Statement
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2022) - CVR Medical Corp. (TSXV: CVM) (OTCQB: CRRVF) ("CVR Medical" or the "Company" or "we") a Canadian listed and US based healthcare company in the medical device market is pleased to announce the completion and filing of its 2022 Q3 Financial Statement. The financial report is posted on SEDAR. About CVR MedicalCVR Medical Corp. is a healthcare company that operates in the medical device industry focused...

Therma Bright Invests in the Development of Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)
Toronto, Ontario--(Newsfile Corp. - December 1, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into an agreement to acquire an interest in a novel technology that utilizes inhaled statins for the treatment of respiratory conditions including asthma, chronic obstructive pulmonary disease ("COPD"), and acute...

Izotropic Completes IzoView Development and Assembly, Prepares for Final Testing
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2022) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers is pleased to announce that it has completed the final engineering of IzoView.IzoView is now fully assembled and being prepared for final software testing and certifications of the pre-commercial model to be used in...

Subscribe to Biotech News